| Bioactivity | Dapoxetine (LY-210448) is an orally active and selective serotonin reuptake inhibitor (SSRI). Dapoxetine can be used for the research of premature ejaculation (PE)[1]. |
| Invitro | Dapoxetine binds to 5-HT, norepinephrine, and dopamine reuptake transporters and inhibits 5-HT, norepinephrine, and dopamine uptake with an order of potency: 5-HT >norepinephrine≫dopamine.Dapoxetine inhibits the uptake of [3H]5-HT by the 5-HT reuptake transporter with a value of 1.12 nM, and Dapoxetine inhibits the uptake of [3H]norepinephrine into cells utilizing the norepinephrine reuptake transporter and uptake of [3H]dopamine by the dopamine reuptake transporter with IC50 values of 202 nM and 1720 nM, respectively.[1] |
| In Vivo | Dapoxetine (oral gavage; 1-10 mg/kg; once daily) significantly inhibits testosterone mediated increase in the prostate weight and relative prostate weight and attenuates testosterone-induced prostatic hyperplasia in rats[2]. Animal Model: |
| Name | Dapoxetine |
| CAS | 119356-77-3 |
| Formula | C21H23NO |
| Molar Mass | 305.41 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Muammer Kendirci, et al. Dapoxetine, a novel selective serotonin transport inhibitor for the treatment of premature ejaculation. Ther Clin Risk Manag. 2007 Jun;3(2):277-89. [2]. Rabab H Sayed, et al. Dapoxetine attenuates testosterone-induced prostatic hyperplasia in rats by the regulation of inflammatory and apoptotic proteins. Toxicol Appl Pharmacol. 2016 Nov 15;311:52-60. |